EUVIMEDEUVIMED entdecken
Systematische Übersicht

Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors

Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, Saba Falakeh, Jasmine Khalilnejad Amiri, Azadeh Goodarzi

Inflammopharmacology · 2025-04 · 33 (4) · 1617-1672

DOI: 10.1007/s10787-025-01675-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammopharmacology, online erschienen am 05.03.2025. Verfasst von Alireza Jafarzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Asadabadi Street, 21St Street, Next to S…. Hauptthemen laut MEDLINE: Biological Products, Skin Diseases, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recent advancements in the treatment of paediatric dermatological conditions have emerged with the introduction of biologics and small molecule inhibitors (SMIs). These therapies target specific inflammatory pathways, which may enhance treatment outcomes for diseases like atopic dermatitis, psoriasis, and alopecia areata. OBJECTIVES: This systematic review seeks to assess the effectiveness and safety of biologics and SMIs for dermatologic conditions in children and adolescents, with an emphasis on randomised clinical trials. METHODS: We performed an extensive literature search across PubMed, Scopus, and Web of Science, following PRISMA guidelines. Studies included in the review were those that analysed systemic treatments using biologics and SMIs in subjects under 18 years of age. We extracted data on participant demographics, treatment regimens, effectiveness outcomes, adverse effects, and follow-up details. The risk of bias in the studies was determined using the Cochrane Risk of Bias Tool (RoB2). RESULTS: From an initial pool of 1,454 studies, 49 articles fitting the inclusion criteria were identified, encompassing 6372 cases. The review found that biologics such as Dupilumab, along with investigational JAK inhibitors like Abrocitinib and Upadacitinib, exhibited considerable efficacy in treating various conditions, particularly atopic dermatitis and psoriasis. Dupilumab specifically demonstrated significant improvements in both disease severity and quality of life. While most reported adverse events were mild to moderate, some serious adverse events were noted with certain treatments. CONCLUSIONS: Biologics and SMIs show great promise as therapeutic options in paediatric dermatology, offering better efficacy compared to traditional treatments. Despite these encouraging findings, additional research is needed to verify their long-term safety, especially in relation to growth and development in younger patients. Future investigations should aim to include a broader range of patient demographics and dermatological conditions beyond those currently studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsSkin DiseasesDermatologic AgentsHumansChildAdolescentInfantDermatitis, AtopicPsoriasisChild, PreschoolRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

ANCA-associated vasculitidesAbrocitinibAdalimumabAlopecia areataApremilastBaricitinibBiologicsCanakinumabDupilumabEfficacyEmerging treatmentEtanerceptInterleukin InhibitorsIxekizumabJAK Inhibitors

Substanzen

Biological ProductsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Asadabadi Street, 21St Street, Next to Shafaq Park, Tehran, 1445613131, Iran.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Islamic Azad Medical University, Tehran Branch, Tehran, Iran.
  • Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Asadabadi Street, 21St Street, Next to Shafaq Park, Tehran, 1445613131, Iran. azadeh_goodarzi1984@yahoo.com.

Zitieren

APA

Jafarzadeh, A., Behrangi, E., Khosravi, M., Falakeh, S., Amiri, J. K., & Goodarzi, A. (2025). Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors. Inflammopharmacology, 33(4), 1617-1672. https://doi.org/10.1007/s10787-025-01675-4

Vancouver

Jafarzadeh A, Behrangi E, Khosravi M, Falakeh S, Amiri JK, Goodarzi A. Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors. Inflammopharmacology. 2025;33(4):1617-1672. doi:10.1007/s10787-025-01675-4

BibTeX
@article{Jafarzadeh2025,
  author = {Jafarzadeh, Alireza and Behrangi, Elham and Khosravi, Mina and Falakeh, Saba and Amiri, Jasmine Khalilnejad and Goodarzi, Azadeh},
  title = {Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors},
  journal = {Inflammopharmacology},
  year = {2025},
  volume = {33},
  number = {4},
  pages = {1617--1672},
  doi = {10.1007/s10787-025-01675-4}
}
Kostenlos starten →